home / stock / pali / pali news

PALI News and Press, Palisade Bio Inc. From 05/14/24

Stock Information
Company Name: Palisade Bio Inc.
Stock Symbol: PALI
Market: NASDAQ
Menu
PALI PALI Quote PALI Short PALI News PALI Articles PALI Message Board
Get PALI Alerts

News, Short Squeeze, Breakout and More Instantly...
PALI - Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update

– Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end – Sufficient cash on hand to execute on business plan and reach clinical and regulatory milestones into 2025 ...
PALI - Expected US Company Earnings on Friday, May 10th, 2024

Jet.AI Inc. (JTAI) is expected to report for Q1 2024 Forian Inc. (FORA) is expected to report $-0.02 for Q1 2024 Square Enix Holdings Co. Ltd (SQNXF) is expected to report for Q4 2024 Qutoutiao Inc. (QTT) is expected to report for Q4 2023 Molecular Partners AG (MOLN) is expected t...

PALI - Palisade Bio Appoints Margery Fischbein to its Board of Directors

Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisadeȁ...

PALI - Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules

Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, is announcing today that it has closed its ...
PALI - Palisade Bio looks to raise $4M in private placement

2024-05-02 08:42:31 ET More on Palisade Bio Palisade Bio stock rallies 50% premarket on colitis drug update Palisade Bio stock rallies nearly 100% on colitis drug analysis Read the full article on Seeking Alpha For further details see: Palisade Bio looks ...

PALI - Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules

Carlsbad, CA, May 02, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, is announcing today that it has entered int...

PALI - Market News Snapshot

2024-05-01 10:41:49 ET DENVER, Colo., May 01, 2024 ( 247marketnews.com )- Brera Holdings (NASDAQ: BREA ), Palisade Bio, Inc. (Nasdaq: PALI ), Getaround (NYSE: GETR ), CytomX Therapeutics, Inc. (Nasdaq: CTMX ), and Predictive Oncology Inc...
PALI - US Companies Moving the Markets, Morning edition
Wed, May 01, 2024 as of 10.00 am ET

A look at the top 10 most actives in the United States Akanda Corp. (AKAN) rose 52.9% to $0.1422 on volume of 108,274,564 shares CytomX Therapeutics Inc. (CTMX) rose 71.8% to $2.8 on volume of 31,588,176 shares Getaround Inc. (GETR) rose 35.9% to $0.2754 on volume of 26,693,135 shares P...

PALI - Palisade Bio stock rallies 50% premarket on colitis drug update

2024-05-01 09:13:26 ET More on Palisade Bio Palisade Bio stock rallies nearly 100% on colitis drug analysis Palisade Bio stock slides 8% amid colitis drug presentation Seeking Alpha’s Quant Rating on Palisade Bio Historical earnings data for Palisade B...

PALI - Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)

Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) before year end Carlsbad, CA, May 01, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or th...
Previous 10 Next 10